Cost effectiveness in the treatment of advanced solid tumours.
When the treatment of advanced cancer is palliative in intent, evaluation of quality of life is of paramount importance in judging the effectiveness of treatment. The balance between adverse effects (costs) and benefits has been particularly difficult to determine with cytotoxic drugs. An approach to this problem using medical audit is described. It has been found to be a reliable method which has demonstrate a highly significant correlation between achievement of objective regression and acquisition of benefit. The method is now undergoing corroboration by a prospective study.
Rubens
R D
RD
ICRF Clinical Oncology Unit, Guy's Hospital, London, U.K.
D000970:Antineoplastic Agents / Q000627:therapeutic use*; D003362:Cost-Benefit Analysis; D006801:Humans; D008485:Medical Audit; D009367:Neoplasm Staging; D009369:Neoplasms / Q000188:drug therapy* / Q000191:economics / Q000473:pathology; D010166:Palliative Care / Q000191:economics; D011788:Quality of Life
D000970:Antineoplastic Agents